In-Depth Validation of Closed-Vial Technology - The authors describe a validation master plan for closed-vial filling technology. - BioPharm International


In-Depth Validation of Closed-Vial Technology
The authors describe a validation master plan for closed-vial filling technology.

BioPharm International
Volume 25, Issue 9, pp. 30-42


As described above, several modifications have been introduced compared with the classical glass-vial technology. To ensure that these modifications meet regulatory requirements and expectations, they have been tested according to the US and European pharmacopeas and to the guidelines published by the International Conference on Harmonization (ICH), and compiled in the validation master plan.

Table I: Overview of the tests performed in the validation master plan.
The tests performed are listed in Table I. They can be split into four parts: the container–closure materials, the behavior of the container closure in various conditions, the specific filling operations, and the overall process.

One crucial aspect of the container–closure is that the container has to be treated by gamma-irradiation to ensure its overall sterility, and not only asepsis. Gamma-irradiation may have physico-chemical effects on the materials. Therefore, to be robust, validation must be performed using worst-case conditions regarding the irradiation dose. To that end, a dose-mapping experiment on the densest pallet (1-mL vials) showed that to ensure a minimum of 25 kGray at the coldest point, the hottest point can receive up to 46 kGray. Therefore, the decision was made to irradiate all the test material at minimum 50 kGray.


Different chapters of the pharmacopeia are applicable to closed-vial materials, as indicated in Table I. Of course, these tests must be conducted only on materials in direct contact with the pharmaceutical drug (i.e., the TPE stopper and the COC vial body).

The toxicity test described in USP <87> Biological Reactivity Tests, In Vitro has been conducted on both vial body and stopper materials. Extract of materials are subjected to the elution test in which L-929 cells are incubated for 48 hours with media used to extract materials. This test was repeated on three batches of each material and did not show any sign of reactivity.

The toxicity test described in USP <88> Biological Reactivity Tests, In Vivo is directly linked to the USP Class VI classification. It combines systemic injection, intracutaneous injection, and intramuscular implantation tests with extracted materials or strips of materials. Based on the results obtained, the material can be classified from Class I up to Class VI. According to the application, a certain level of classification is mandatory (e.g., USP Class VI is mandatory for permanent implantation such as prosthesis). For injectable containers, Class IV is acceptable. Nevertheless, as most of container materials meet the most stringent conditions (i.e., class VI), this one became a recommended standard. To perform a complete range of tests, the products must be extracted with four different solutions: 0.9% sodium chloride, 1:20 alcohol solution in sodium chloride, 0.9% polyethylene glycol 400, and vegetable oil. For both vial body and stopper materials and with all extraction solutions, the test was performed on three different batches and no toxicity was recorded, showing that USP Class VI requirements are met.

Other tests were performed regarding material physico-chemical properties. The US Pharmacopeia requires a series of tests on polymers in USP General Chapter <661>. These tests are limited to nonvolatile residues, residues on ignition, heavy metals, and buffer capacity. Some polymers such as polyethylene require specific tests but these are not applicable to COC. In the European Pharmacopoeia , chapter EP 3.1.3 Polyolefines, is dedicated to polyolefin. Although COC does not fall in that category, because the definition of polyolefin is limited to "polyethylene or co-polymer of ethylene with less than 25% of another organic compound," it was still decided to conduct that series of tests on COC. The vial body passed all these tests.

Concerning the tests to be conducted on the elastomeric closure, because USP <381> Elastomeric Closures for Injections contains the in vitro and in vivo tests described here as well as other tests harmonized with those described in EP 3.2.9 Rubber Closures for Containers, EP 3.2.9 for single-dose container was selected. This chapter describes mixing chemical tests on elastomeric closure extracts and mechanical tests such as fragmentation and penetrability on the whole stopper. The TPE stopper successfully passed all these tests for single-use container.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here